update provide this key for thanks approach and Infinity's plans year the an to Jayne, to this Thanks, on for company. we excited quarter us everyone milestones as joining of on We're activities for remainder the our and today.
signaling immunosuppressive suppressor inhibitor. in antitumor activation. function, important our macrophages By and make pro-tumor immune and MDSCs, IPI-XXX, a reducing reprogramming inhibiting plays cells from to unique IPI-XXX or first suppression continue derived a class role them oral We thus with immune myeloid selective increasing PIX-kinase-gamma within in PIX-kinase-gamma progress
in eliminating study checkpoint and Xb immunotherapies, many play the the role including Phase existing macrophages effectiveness that inhibitors. contributes MDSCs of an knowledge MARIO-X suggesting important of to robust Our body
immune the checkpoint advanced It patients we development We in are immunotherapies or unmet advancing currently the initially of approximately do with who IPI-XXX is address existing evaluating in tumors. that not either inhibitor nivolumab, a respond to respond our by needs hope of IPI-XXX, who XXX PD-X work can ultimately patients combination to and with relapse. solid
expansion that reported cohorts immune and for acquired tolerated, rationale selected inhibitors. our patients in resistance with type two compelling patients indicating cell with these increases of therapy. designed inhibitor single-agent Five solid by neck. prior to checkpoint shared tumors three of combination As intrinsic from translational or reverse five been have seeking Xb with suppression distinct prospectively to three In as the clinically expected data trial. immune findings in fifth tumor with These first cohorts well nivolumab. a with that monotherapy intrinsic triple for portion seven in cohort and and demonstrate patients cohort are is peripheral support the the therapy. squamous are we blood to key IPI-XXX cohorts, nivolumab preclinical clinical in negative the evaluating responses inhibitor selection to These and treated and resistance associated with fourth of to IPI-XXX, breast Phase intrinsic evaluates is activation. cohorts level and in checkpoint our of in activity. reduces clinical carcinoma immediately And are checkpoint the with the refractory which cohorts are the whom directed cancer, our for to objective of is The to baseline in result These high at ASCO, on acquired we from cancer, scientific patients active not in biopsies, the and combination MDSCs, data seen IPI-XXX have to cell a work. combination mechanism with paired both The each patients date confirm to are advanced tumor checkpoint blood resistance or combination patients lung melanoma inhibitors non-small head data
therapy with The no checkpoint inhibitors little patients first settings IPI-XXX refractory is in that to known treatment to where activity. be benefits to checkpoint shown inhibitor has
initially second respond overcome a for IPI-XXX inhibitor there design, for that is settings significant patients acquired these relapse checkpoint to activity in patients is help with IPI-XXX resistance can checkpoint unmet therapy. and high a treatment in The By to blockade whom a bar ultimately establish very that need.
And efforts development BMS' collaboration our cancer late-breaking signals suffering patients In addition, of naive These to This adrenocortical cohorts, in saw the from with expansion in combination with difficult Bristol-Myers to XXX types by and of IPI-XXX Society patients a X accepted nivolumab. Immunotherapy announced cancer, dose-escalations morning, as of treat checkpoint in We're tumor solid cancer. ongoing two with development randomized to activity and we've treatment support we improve plans in and in we pleased we very in Cancer, urothelial and advancing Squibb. combination global poster we sharing where coming this of Annual approximately monotherapy collaboration data with presentation. our SITC, the the or and following IPI-XXX. our a study these patients options which appreciate shared encouraging to to initiate from are Meeting Phase for of mesothelioma IPI-XXX, for an We for clinical Saturday, inhibitor the been urothelial forward support called IPI-XXX update at a progress look expanded MARIO-XXX. responses advanced
therapies are Arcus to two triple triple in ovarian complementary Biosciences investigate IPI-XXX of two action. therapies cancer. also We in work breast first-in-class our and combination novel negative include cancer which continue with combinations, mechanisms with These
joining to same on in today's population. IPI-XXX's doublets be will call. to assess from triplet contribution also to Agresta comparing the We patient pleased them to able the these Sam Dr. data the us We're Arcus' by have
a innovative medicine precision in that, IDH the us that has recently, call Sam led TIBSOVO, as drug affairs Medical of his AML Agios, Infinity cancer Officer, IDHIFA medicines development August tremendous development clinical working already turn with from and for joined over Most this study with regulatory and X mutations. contributions to our we Chief targeted including to made and morning. harboring and oncology first-in-class finalize Sam. work, both at brings As past experience Sam the orally Sam roles. patients urothelial the to in BMS a wealth available reminder, our to of development announced With I'll cancer Phase in
